US.BSX · Boston Scientific

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.6086011379539285,
        "turnoverUsdM": 2175.8370035797075,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BSX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 42.7172,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 2.5,
        "volume_score": 3
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 7.2,
      "take_profit_price": 50.1963,
      "target_multiplier": 1.9,
      "technical_strength": 1.98,
      "take_profit_percent": 9
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2470206121343446,
    "stopLossPercent": 7.217202275907857,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 78.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 25
  },
  "market": {
    "ma20": 44.3505,
    "ma50": 47.0118,
    "close": 46.04,
    "prevClose": 46.06,
    "avgVolume20": 19141725,
    "volumeRatio": 2.47,
    "changePercent": -0.04
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 25,
    "details": {
      "ret_5d": 0.07144521759366995,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 25,
      "vcp_bonus": 0,
      "vol_ratio": 2.4968047728044187,
      "ret_points": 12,
      "vol_points": 8,
      "range_ratio": 3.2639937876267022,
      "volat_points": 4,
      "day_range_pct": 0.094048651302158,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 78.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 98,
        "contribution": 4.9
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 7.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 52,
        "contribution": 7.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 61,
        "contribution": 6.1
      },
      {
        "raw": 20.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.67,
        "contribution": 20.3
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 53.3,
    "details": [
      "基本面分析總分: 4.9/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 7.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.1/10分",
      "技術信號分析總分: 20.3/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.9,
      "資金流": 9.2,
      "市場環境": 7.8,
      "情緒分析": 3,
      "技術信號": 20.3,
      "風險管理": 6.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 2175.8370035797075,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BSX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.21
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 704.3249969000001,
                "ma50": 715.8034021999999,
                "name": "QQQ",
                "close": 661.63,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.7855067000002,
                "ma50": 744.6632029799998,
                "name": "SPY",
                "close": 729.46002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.6086011379539285,
          "atrPoints": 2,
          "cciPoints": 3.2,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141057181,
                "url": "https://finnhub.io/api/news?id=dd903a17dd6bb593b57b27c3d22b17b4e804f6778696ec0c89525d0dc118e720",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.",
                "category": "company",
                "datetime": 1785351843,
                "headline": "Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ..."
              },
              {
                "id": 141054322,
                "url": "https://finnhub.io/api/news?id=cf8192083410f5302255e882bbbcfe0c984669f204e3d40254a9269ee695f7c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785335403,
                "headline": "Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141053184,
                "url": "https://finnhub.io/api/news?id=ce97b59f060ad8b95f2959cd2b75d32dd94b2eeec0b0f7376a7179667d351683",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785327905,
                "headline": "Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141054640,
                "url": "https://finnhub.io/api/news?id=8b0c7a25f7dfbcf0b87315813d91b2d5f6599e35e023d5d8e7a9f802d7f0256a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsLauren Tengler - Director of Investor...",
                "category": "company",
                "datetime": 1785326595,
                "headline": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141051895,
                "url": "https://finnhub.io/api/news?id=e3c22d3b43e4606b1490e9974d204db76695ca49fc89ec8dc2201c7a8e12db00",
                "image": "https://www.chartmill.com/images/uploads/earnings_article_1_defce97180.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific beat Q2 2026 estimates with $0.86 adjusted EPS (beat 3%) and $5.442B revenue (inline). Shares rose 4.2% pre-market on strong earnings performance.",
                "category": "company",
                "datetime": 1785324135,
                "headline": "Boston Scientific (NYSE:BSX) Tops Q2 2026 Estimates on Adjusted EPS Beat"
              },
              {
                "id": 141052213,
                "url": "https://finnhub.io/api/news?id=791fc474bd03c53607709e9659d73f420b282aeef62c2460994ebb44d448bdcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785323485,
                "headline": "Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations"
              },
              {
                "id": 141041184,
                "url": "https://finnhub.io/api/news?id=a59c44f2f68192da00049ebcdbdc9d8dcf8bd95fb926d1266440b0f62b010d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.",
                "category": "company",
                "datetime": 1785229262,
                "headline": "What To Expect From Boston Scientific’s (BSX) Q2 Earnings"
              },
              {
                "id": 141006570,
                "url": "https://finnhub.io/api/news?id=8f3ed990bac78bbe2aab4028c06f246d6f29d4c4e20085b579d57ee033147671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784898904,
                "headline": "Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures"
              }
            ],
            "raw_source": [
              {
                "id": 141058553,
                "url": "https://finnhub.io/api/news?id=049e0667ac38c1bdb506783a563224f7331980aa36cbfdbcd5b33f0e09afe9e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi",
                "category": "company",
                "datetime": 1785355438,
                "headline": "Boston Scientific Q2 Earnings Call Highlights"
              },
              {
                "id": 141056998,
                "url": "https://finnhub.io/api/news?id=a7dcfe2fe96bffadb525443192a34a9ac97e51b8d93183b0230da5d85aa77588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and",
                "category": "company",
                "datetime": 1785354366,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 141057181,
                "url": "https://finnhub.io/api/news?id=dd903a17dd6bb593b57b27c3d22b17b4e804f6778696ec0c89525d0dc118e720",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.",
                "category": "company",
                "datetime": 1785351843,
                "headline": "Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ..."
              },
              {
                "id": 141056192,
                "url": "https://finnhub.io/api/news?id=c766f88e616916fe8e40600df5afe7cbf8d7ee2d3376090d27e1bd4192e4fb2e",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1785348302,
                "headline": "Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 141055665,
                "url": "https://finnhub.io/api/news?id=689226e9857ec7cac1da65efb7e5fb2d018a298a67a1cf8ffa7ff085cefe30ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1%",
                "category": "company",
                "datetime": 1785346406,
                "headline": "Sector Update: Healthcare Stocks Edge Lower in Afternoon Trading"
              },
              {
                "id": 141055135,
                "url": "https://finnhub.io/api/news?id=4dc12047b41ce397449a1555482561b53f25523ac38d9977a9ca33d8022dc596",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
                "category": "company",
                "datetime": 1785344700,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 141055900,
                "url": "https://finnhub.io/api/news?id=3a1fd910fa3e1a2d3a3669c17c8dbf9fc86f391f098f6a4b78c3414f25327051",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...",
                "category": "company",
                "datetime": 1785341220,
                "headline": "Boston Scientific beats second quarter expectations, raises full-year outlook"
              },
              {
                "id": 141054320,
                "url": "https://finnhub.io/api/news?id=56478597088739a9ef29ba72345d948806b4209219b8892449b9c357c2985673",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.",
                "category": "company",
                "datetime": 1785340295,
                "headline": "Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook"
              },
              {
                "id": 141054047,
                "url": "https://finnhub.io/api/news?id=73d238629d498efdb827745e5672b94a6c855e68df7092faf6295dcac9246948",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c",
                "category": "company",
                "datetime": 1785338822,
                "headline": "Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device"
              },
              {
                "id": 141054322,
                "url": "https://finnhub.io/api/news?id=cf8192083410f5302255e882bbbcfe0c984669f204e3d40254a9269ee695f7c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785335403,
                "headline": "Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141053182,
                "url": "https://finnhub.io/api/news?id=1a5f6f8eecfddc754781d5211dbae33b4ca373ffded93226ce2e0035f4790b66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41",
                "category": "company",
                "datetime": 1785330176,
                "headline": "Boston Scientific Q2 2026 earnings: profit forecast cut on Watchman slowdown"
              },
              {
                "id": 141054323,
                "url": "https://finnhub.io/api/news?id=a3aef00cbe41993bf01f0396883fd69b084a50114577f7987ef97535873fe920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.",
                "category": "company",
                "datetime": 1785330060,
                "headline": "Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs"
              },
              {
                "id": 141052519,
                "url": "https://finnhub.io/api/news?id=d12ea2b97a7b8de7d8605f8f43bbe2a535312469ed9993773e3e6f01acd75ef9",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.",
                "category": "company",
                "datetime": 1785328501,
                "headline": "Get insights into the top movers in the S&P500 index of Wednesday's pre-market session."
              },
              {
                "id": 141053183,
                "url": "https://finnhub.io/api/news?id=6d6b65e808e57546e505abf68d625859db130db801549d733a6fec3f8143a9b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.",
                "category": "company",
                "datetime": 1785328033,
                "headline": "Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares"
              },
              {
                "id": 141053184,
                "url": "https://finnhub.io/api/news?id=ce97b59f060ad8b95f2959cd2b75d32dd94b2eeec0b0f7376a7179667d351683",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785327905,
                "headline": "Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141054044,
                "url": "https://finnhub.io/api/news?id=44c001b8eb09651befca60290bb06b4467e6a5de6f1f89228a1a7bf643fd5e53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "A busy afternoon of earnings from Meta and Microsoft comes as the Fed is expected to hold rates",
                "category": "company",
                "datetime": 1785327180,
                "headline": "Dow Jones down over 800 points as Trump lashes out ahead of Fed decision"
              },
              {
                "id": 141054640,
                "url": "https://finnhub.io/api/news?id=8b0c7a25f7dfbcf0b87315813d91b2d5f6599e35e023d5d8e7a9f802d7f0256a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsLauren Tengler - Director of Investor...",
                "category": "company",
                "datetime": 1785326595,
                "headline": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141052917,
                "url": "https://finnhub.io/api/news?id=c73ec1e45071df7ab6cf027726410cb65ae0a0f6ec8c56db89e4703ca4176140",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders",
                "category": "company",
                "datetime": 1785326392,
                "headline": "Stocks Mostly Up Pre-Bell Ahead of Fed Rate Decision, Big Tech Earnings"
              },
              {
                "id": 141055901,
                "url": "https://finnhub.io/api/news?id=587de705b5880896f838b010d6e7960265583fbeb709acf2a7b91ab7d080732c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.",
                "category": "company",
                "datetime": 1785326100,
                "headline": "Boston Scientific again cuts 2026 guidance"
              },
              {
                "id": 141051895,
                "url": "https://finnhub.io/api/news?id=e3c22d3b43e4606b1490e9974d204db76695ca49fc89ec8dc2201c7a8e12db00",
                "image": "https://www.chartmill.com/images/uploads/earnings_article_1_defce97180.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific beat Q2 2026 estimates with $0.86 adjusted EPS (beat 3%) and $5.442B revenue (inline). Shares rose 4.2% pre-market on strong earnings performance.",
                "category": "company",
                "datetime": 1785324135,
                "headline": "Boston Scientific (NYSE:BSX) Tops Q2 2026 Estimates on Adjusted EPS Beat"
              },
              {
                "id": 141052212,
                "url": "https://finnhub.io/api/news?id=00bb7c15e48e58f3ac9b2a3495b2878951f5682677382d2c0f79a23439317f05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates.",
                "category": "company",
                "datetime": 1785323704,
                "headline": "Boston Scientific stock gains as medical device maker tops Q2 forecasts"
              },
              {
                "id": 141052213,
                "url": "https://finnhub.io/api/news?id=791fc474bd03c53607709e9659d73f420b282aeef62c2460994ebb44d448bdcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785323485,
                "headline": "Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations"
              },
              {
                "id": 141052214,
                "url": "https://finnhub.io/api/news?id=ef9571db900e34a64ad62da4d488d948e928062f2498676ef159890cde6b9977",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared t",
                "category": "company",
                "datetime": 1785321000,
                "headline": "Boston Scientific announces results for second quarter 2026"
              },
              {
                "id": 141052498,
                "url": "https://finnhub.io/api/news?id=67f13e7dce4a4153cb00fc345b6d20396e901f73d3b9db2613ae57a61a2c4e48",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "2026-07-29. The following slide deck was published by Boston Scientific Corporation in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785313881,
                "headline": "Boston Scientific Corporation 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141045528,
                "url": "https://finnhub.io/api/news?id=ad7f745883259fc021a3b634be189425acb7e3cedaa328951b9890dbbb1bb36c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston expects its restructuring plan to cost between $700m and $800m and be completed by the end of 2029.",
                "category": "company",
                "datetime": 1785256447,
                "headline": "Boston Scientific expects headcount reductions amid restructuring initiative"
              },
              {
                "id": 141041757,
                "url": "https://finnhub.io/api/news?id=e608a003141f5e728800fd2bcdd8587566b862645fcbc91a95de09a83cfd0975",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Cloud-based AI algorithm supports implantable cardiac monitors from all major manufacturers, reducing false-positive alerts by up to 76% while maintaining high sensitivity for true events CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation ILR ECG Analyzer, marking Implicity's third FDA cleara",
                "category": "company",
                "datetime": 1785239100,
                "headline": "Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance"
              },
              {
                "id": 141041716,
                "url": "https://finnhub.io/api/news?id=2a86e4b8fd92ac62a83ec851d35f1e19f535387b356654c5c93fd6c2bfdd1cb0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.",
                "category": "company",
                "datetime": 1785238969,
                "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More"
              },
              {
                "id": 141043888,
                "url": "https://finnhub.io/api/news?id=a4eacf80b0bec7cbeb6b08cfd1d10ae96ce0f50812ce33b715c76e124ae4557f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.",
                "category": "company",
                "datetime": 1785235982,
                "headline": "Boston Scientific to restructure, taking up to $800M in charges"
              },
              {
                "id": 141041184,
                "url": "https://finnhub.io/api/news?id=a59c44f2f68192da00049ebcdbdc9d8dcf8bd95fb926d1266440b0f62b010d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.",
                "category": "company",
                "datetime": 1785229262,
                "headline": "What To Expect From Boston Scientific’s (BSX) Q2 Earnings"
              },
              {
                "id": 141041557,
                "url": "https://finnhub.io/api/news?id=7d3fe4c0d23f407ac74fb782e56ffe787cecacb6384ae5c0e8ee27f650627233",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259148943/image_2259148943.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "The Silvant Large Cap Growth SMA returned +14.61% (gross)/+13.79% (net) for the quarter compared to the Russell 1000 Growth Index's return of +16.74%. Read more here.",
                "category": "company",
                "datetime": 1785224400,
                "headline": "Virtus Large Cap Growth SMA Q2 2026 Portfolio Update"
              },
              {
                "id": 141045482,
                "url": "https://finnhub.io/api/news?id=cbc8875e129069758ebfd5b5605cda1817a6812470a9ca12da3652e9a217b579",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm",
                "category": "company",
                "datetime": 1785168637,
                "headline": "Boston Scientific Approves 2026 Global Restructuring Program; Plan Intends To Cut Headcount; Expects ~$700M - $800M As Pre-Tax Charges; Plan Expected To Reduce Annual Pre-Tax Expenses by $500M"
              },
              {
                "id": 141035129,
                "url": "https://finnhub.io/api/news?id=c92ef4a473af545abf93085c0feb833d345113b7ee6e12a65912c65c41f0d0ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.",
                "category": "company",
                "datetime": 1785167220,
                "headline": "J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?"
              },
              {
                "id": 141045483,
                "url": "https://finnhub.io/api/news?id=7700dd908c3d15ced2f5514f0ac9ae15f312832be50483ca63d40f401f379b1c",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "https://news.bloomberglaw.com/health-law-and-business/boston-scientific-gets-42-million-stent-patent-verdict-reversed",
                "category": "company",
                "datetime": 1785154672,
                "headline": "'Boston Scientific Gets $42 Million Stent Patent Verdict Reversed' - Bloomberg"
              },
              {
                "id": 141045484,
                "url": "https://finnhub.io/api/news?id=2ef5dd24476682cde144ac7144ab997d8c5c0682096fd45ea0ff6a07814cf052",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.23% on an annualized basis producing an average annual return of 13.77%. Currently, Boston Scientific has a market capitalization of",
                "category": "company",
                "datetime": 1785149153,
                "headline": "Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 141033415,
                "url": "https://finnhub.io/api/news?id=2bbae2db157ab89f4609282fcd67c4cb0b54036c57251be7c12a1e653e5bf49c",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Oppenheimer  analyst Suraj Kalia   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $90 to $85.",
                "category": "company",
                "datetime": 1785143900,
                "headline": "Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $85"
              },
              {
                "id": 141006570,
                "url": "https://finnhub.io/api/news?id=8f3ed990bac78bbe2aab4028c06f246d6f29d4c4e20085b579d57ee033147671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784898904,
                "headline": "Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures"
              },
              {
                "id": 141005373,
                "url": "https://finnhub.io/api/news?id=b36b031e7ee377bc4138167b006d1828b02fd77c1e500f55b43a05f249614da2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784895900,
                "headline": "6 Medical-Device Stocks to Buy After a Massive Selloff"
              },
              {
                "id": 141003245,
                "url": "https://finnhub.io/api/news?id=2ebd8eda6820cc2c6f0a825f7bed40d44a97ae7a597344157a7a0eb81e98b72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784871000,
                "headline": "Medical-Device Stocks Are in the Bargain Bin. 6 to Buy."
              },
              {
                "id": 141002553,
                "url": "https://finnhub.io/api/news?id=3fb33829d4e318309e8e056c3e67b301a229a4790f57ba382a422d50ecc0c59d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/915092842/image_915092842.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "For months I've had an uneasy feeling about the sustainability of this great bull run.",
                "category": "company",
                "datetime": 1784854800,
                "headline": "Have We Entered A Stealth Bear Market?"
              },
              {
                "id": 140996690,
                "url": "https://finnhub.io/api/news?id=85af9e8893acc6773c696c8ffbce2fa38f27f38ee6fd643adf77b9f3130959f1",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784813736,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140991408,
                "url": "https://finnhub.io/api/news?id=ba0381e681b8e226e29647244ebeaa94d248c219e56ba8f2164c63dbfd7d6836",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This milestone marks the formal start of large scale clinical testing for the Faraflex system. Boston Scientific is a major player in cardiac rhythm and electrophysiology devices, and the FARADIGM trial adds another clinical program to that portfolio. Atrial fibrillation treatments have been an area...",
                "category": "company",
                "datetime": 1784790803,
                "headline": "Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial"
              },
              {
                "id": 140983262,
                "url": "https://finnhub.io/api/news?id=4804a7123f414ba8d9f37bc3eaec1a74f90e38ae8851204e95e2a8758f3a314c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension between recent share price weakness and what the broader metrics suggest about value. Boston Scientific shares are down about 58.1% over the past year, which sharply resets expectations around what investors are willing to pay for the business. Upcoming earnings and progress integrating recent device acquisitions may support sentiment, while ongoing Class...",
                "category": "company",
                "datetime": 1784733132,
                "headline": "Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump"
              },
              {
                "id": 140982003,
                "url": "https://finnhub.io/api/news?id=8cf71b138d3761650389a711f4dda8648ffbcf5ba464e7dcc92e0740d0fb8194",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...",
                "category": "company",
                "datetime": 1784726003,
                "headline": "Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued"
              },
              {
                "id": 140977765,
                "url": "https://finnhub.io/api/news?id=a31c7dd1d6baca0b0d12b261041c20bd387935179f3276e4a502f27b75b1c34d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.",
                "category": "company",
                "datetime": 1784671204,
                "headline": "Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 140974912,
                "url": "https://finnhub.io/api/news?id=bbdead80568b813174817288369cedcdbc1558cbe69a3fa5d808987e69a9b82d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.",
                "category": "company",
                "datetime": 1784660157,
                "headline": "Why BSX Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 140971693,
                "url": "https://finnhub.io/api/news?id=a44cd51e74b74d214cb2c38b67dfde3d97fb31250c3bd9176d83a7e1f30be12f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.",
                "category": "company",
                "datetime": 1784641620,
                "headline": "Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?"
              },
              {
                "id": 140971260,
                "url": "https://finnhub.io/api/news?id=2344fdefceebd65f91360aefc32faaadaf2f4e51f7cfcf30b5de5f02d820a46c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253086812/image_2253086812.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Read more here.",
                "category": "company",
                "datetime": 1784633100,
                "headline": "Artisan Value Fund Q2 2026 Portfolio Update"
              },
              {
                "id": 140962070,
                "url": "https://finnhub.io/api/news?id=1ebbbe08a8b80b830d991a30a1fcb84f31b2ff57e24f8f5911a74c91ef024e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "ASI DATAMYTE, Inc. (\"DATAMYTE\"), a leading provider of production and quality management solutions serving over 1000 manufacturers including Ford, Boston Scientific, Northrop Grumman, CS Wind, Stellantis, Boeing, Tesla, Gillette, Borg Warner, Cabinetworks Group, Foxconn, Pepsico, GM, and more, announced today that it has achieved ISO/IEC 27001:2022 certification for the information security management system (ISMS) supporting Digital Clipboard, its cloud-based, no-code manufacturing workflow pla",
                "category": "company",
                "datetime": 1784567340,
                "headline": "DATAMYTE Achieves ISO/IEC 27001:2022 Certification for Digital Clipboard, Its No-Code Manufacturing Workflow Platform"
              },
              {
                "id": 140970643,
                "url": "https://finnhub.io/api/news?id=6977fec31dc682ec66e7e5f7a0adbda1a62913b9c702ae32e5158f8563006d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.",
                "category": "company",
                "datetime": 1784554800,
                "headline": "3 Medical Device Stocks Giving Investors a Different Healthcare Play"
              },
              {
                "id": 140951754,
                "url": "https://finnhub.io/api/news?id=6ba6159069d25ba45726b5c1d6ff6db30fd98807f5de1cad5c47a5f9d5cff570",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average.",
                "category": "company",
                "datetime": 1784376900,
                "headline": "Why Intuitive Surgical’s Strong Quarter Still Spooked Investors"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140932973,
                "url": "https://finnhub.io/api/news?id=0504e442cf7f265bb43b0e44d54c0386af3ed0aa7fd4f592d362e90177bbdfa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.",
                "category": "company",
                "datetime": 1784298660,
                "headline": "J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140929637,
                "url": "https://finnhub.io/api/news?id=fc4e117a9c718f7808b89a3fa41ab1d19e66eedc7d8fc5afe48cf96d58817600",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158103448/image_2158103448.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing.",
                "category": "company",
                "datetime": 1784261160,
                "headline": "Parnassus Growth Equity Fund Q2 2026 Portfolio Activity"
              },
              {
                "id": 140920976,
                "url": "https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.",
                "category": "company",
                "datetime": 1784210345,
                "headline": "Why Abbott Stock Is Reimagining Its Future"
              },
              {
                "id": 140924389,
                "url": "https://finnhub.io/api/news?id=f470f02c721b90a6be6c20f1626bcc7c183f489b91e241779d72be19dac4307f",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Truist Securities  analyst Richard Newitter   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $64 to $62.",
                "category": "company",
                "datetime": 1784201996,
                "headline": "Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $62"
              },
              {
                "id": 140916530,
                "url": "https://finnhub.io/api/news?id=4ae758c56242a715639f02c09ddd7ba87402ba98e06380b5c599af0e5d87f754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "SpaceX, IBM and Boston Scientific fell to 52-week lows on Wednesday as Wall Street concerns and profit-taking sent the stocks lower.",
                "category": "company",
                "datetime": 1784171217,
                "headline": "Why Did SPCX, IBM, BSX Drop To 52-Week Lows Today?"
              },
              {
                "id": 140909871,
                "url": "https://finnhub.io/api/news?id=958c1516fca889fe8c88a3fe6decda835bbe773884c027229e49beba9f585e79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784127677,
                "headline": "Boston Scientific (BSX): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140924390,
                "url": "https://finnhub.io/api/news?id=40baa197c2e3ee9ec555ac37182c968d3d10ae8c584a13a229081ac2cf553210",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Mizuho  analyst Anthony Petrone   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $90 to $70.",
                "category": "company",
                "datetime": 1784125326,
                "headline": "Mizuho Maintains Outperform on Boston Scientific, Lowers Price Target to $70"
              },
              {
                "id": 140906869,
                "url": "https://finnhub.io/api/news?id=a1287c9ee7e8bd574c7931b2498a82914dd1c65957ed150c1d0295f97de31689",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "With an upside potential of 62.55%, Boston Scientific Corporation (NYSE:BSX) is among the 12 Strong Buy Stocks with High Upside According to Analysts. On July 8, Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary […]",
                "category": "company",
                "datetime": 1784107276,
                "headline": "Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside"
              },
              {
                "id": 140904923,
                "url": "https://finnhub.io/api/news?id=0e100f96c6d5b996500eeb5faba8392eacec9ee5ce751d792601ba1c8923ce9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...",
                "category": "company",
                "datetime": 1784077936,
                "headline": "Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?"
              },
              {
                "id": 140904327,
                "url": "https://finnhub.io/api/news?id=0eb4b593eb9fa7bafb2b6062a0bc6eb9855eab3f99b86b5e5836eedd7802acb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.",
                "category": "company",
                "datetime": 1784066402,
                "headline": "Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note"
              },
              {
                "id": 140898224,
                "url": "https://finnhub.io/api/news?id=4a3e47be628e3e7507616b74074fceaa3fe9ca6d9916945fc912e01a6834ee7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.",
                "category": "company",
                "datetime": 1784037240,
                "headline": "Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?"
              },
              {
                "id": 140895350,
                "url": "https://finnhub.io/api/news?id=56392c5613eca56c189c98c23461b49b1ee98906f44c4285a191c6e347349fc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
                "category": "company",
                "datetime": 1784018351,
                "headline": "1 Large-Cap Stock with Exciting Potential and 2 We Turn Down"
              },
              {
                "id": 140894719,
                "url": "https://finnhub.io/api/news?id=0696d9a22b1282c2f8fcc200711ba2063bff307e55a7c7e92466a4ad93a64192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The",
                "category": "company",
                "datetime": 1784014200,
                "headline": "ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board"
              },
              {
                "id": 140885071,
                "url": "https://finnhub.io/api/news?id=71b31314daf117ab4b7a113eb37cfe524f5210f5754749ce4767d53f3ef0320c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Opportunities in the nerve repair biomaterials market include advancements in regenerative medicine, rising demand for minimally invasive procedures, and smart biomaterials integration. Growth is driven by increased traumatic brain injuries, aging populations, and regional expansion, especially in Asia-Pacific. Nerve Repair Biomaterials Market Nerve Repair Biomaterials Market Dublin, July 13, 2026 (GLOBE NEWSWIRE) -- The \"Nerve Repair Biomaterials Market Report 2026\" has been added to ResearchAn",
                "category": "company",
                "datetime": 1783942080,
                "headline": "Comprehensive Nerve Repair Biomaterials Market Report Published, Profiles Medtronic, Stryker, Boston Scientific, and 20 Other Key Players"
              },
              {
                "id": 140889672,
                "url": "https://finnhub.io/api/news?id=cdcd346c1e3eb2d197e7c415f4ae480c3c89b2e8c6b735ade6838bd2f03f01f9",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "RBC Capital  analyst Shagun Singh   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $100 to $85.",
                "category": "company",
                "datetime": 1783937654,
                "headline": "RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $85"
              },
              {
                "id": 140884477,
                "url": "https://finnhub.io/api/news?id=f5af8735e47fe5edb74184a36858c8c53d5e8a2b1191e0f0508a1fba28984438",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
                "category": "company",
                "datetime": 1783935737,
                "headline": "1 Stock Under $50 to Keep an Eye On and 2 We Brush Off"
              },
              {
                "id": 140878607,
                "url": "https://finnhub.io/api/news?id=75102b4a65fb2e4c95a746c1c01dcb524d8027d7c0d752a8dad8ee3837a86874",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Stocks to Buy in 2026 According to Billionaire D.E. Shaw. Boston Scientific Corporation (NYSE:BSX) is one of the largest medical device companies in America. Its shares are down by 56% over the past year and by 52% year-to-date. Jefferies was out with a devastating note […]",
                "category": "company",
                "datetime": 1783865064,
                "headline": "Boston Scientific Corporation (BSX) Is A Stock To Buy According To D. E. Shaw"
              },
              {
                "id": 140863143,
                "url": "https://finnhub.io/api/news?id=c2335268121a8c88c3b7265a8a8c47e890caa5b607b444b92d0833f6cf600871",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1783690202,
                "headline": "Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?"
              },
              {
                "id": 140855266,
                "url": "https://finnhub.io/api/news?id=dd632358d0cd47410e40b1a033edd5d547c0d27f3c140cfda837678f6d86e7a4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/09/Showing-Financial-Interface-With-Hologra.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "July brings a sharp rotation trade in markets as investors shift from top performers to beaten-down names.",
                "category": "company",
                "datetime": 1783611903,
                "headline": "'Selling Winners, Buying Losers': Tech Stocks Drop as Energy Jumps to Start H2"
              },
              {
                "id": 140852127,
                "url": "https://finnhub.io/api/news?id=3dc0ae22f59ecc076a1a15b91bdc68fa65b5f68b674058d014aa38fddece5920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.",
                "category": "company",
                "datetime": 1783604422,
                "headline": "The Wide Chasm Priced Into Boston Scientific Stock"
              },
              {
                "id": 140852128,
                "url": "https://finnhub.io/api/news?id=0d8d5355ebff870c994dea78b71564f062bb6a51ab8e04cbf1a91b3ad27b8cd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.",
                "category": "company",
                "datetime": 1783591200,
                "headline": "J&J wins FDA approval for dual-energy ablation catheter"
              },
              {
                "id": 140848746,
                "url": "https://finnhub.io/api/news?id=a495f175979ec12d03687b7b56fbbe0e0b4ee0f002b6e8cdfa4df8b71e35c5c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Steve Cohen, head of Point72 Asset Management, dumped tech stocks and bought this unloved healthcare company.",
                "category": "company",
                "datetime": 1783578900,
                "headline": "Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock"
              },
              {
                "id": 140840581,
                "url": "https://finnhub.io/api/news?id=97e341c2e51d166601008fe13338b21e416c3cf92f2f610cc98c7bdfa93190d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Neuspera Medical today highlighted that the Centers for Medicare & Medicaid Services (CMS) has confirmed the assignment of the billing code for the Neuspera Sacral Neuromodulation System (SNM) to payment level APC 5464 in the proposed CY 2027 Outpatient Prospective Payment System Rule.1 The assignment provides the externally powered integrated SNM (iSNM) system the same Medicare payment as all other neuromodulation implantable therapies for urinary urge incontinence. The rule also increases the",
                "category": "company",
                "datetime": 1783515840,
                "headline": "Neuspera Integrated Sacral Neuromodulation System (iSNM) to Receive Same Medicare Payment as Legacy Implantable SNM Devices Under Proposed 2027 CMS Rule"
              },
              {
                "id": 140843818,
                "url": "https://finnhub.io/api/news?id=f6229ab9177ff16601f8b157e4837c9bbf825e58ccef8b34cc312917a09e6d40",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Needham  analyst Mike Matson   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $77 to $57.",
                "category": "company",
                "datetime": 1783491934,
                "headline": "Needham Maintains Buy on Boston Scientific, Lowers Price Target to $57"
              },
              {
                "id": 140830065,
                "url": "https://finnhub.io/api/news?id=3c61c162eeb4a4ff55bbbf7eb416d76bd56a1411992abae065eed559761e61eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.",
                "category": "company",
                "datetime": 1783430548,
                "headline": "How To Target A 10% Yield While Catching The BSX Stock Knife?"
              },
              {
                "id": 140827192,
                "url": "https://finnhub.io/api/news?id=8c343f65b52eab2ce5875d235dbe8f631430e57169882f7c7aa4d2cafa3aa8d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock moves after clinical results and index changes Boston Scientific (BSX) has come into focus after promising clinical results coincided with multiple index removals and fresh analyst commentary on its Watchman device franchise and utilization trends. Shares recently moved higher, supported by the clinical update and reports of insider buying, even as analysts highlighted slower Watchman growth and trimmed their expectations. At the same time, Boston Scientific was...",
                "category": "company",
                "datetime": 1783402130,
                "headline": "Is Boston Scientific (BSX) Undervalued As Clinical Results Lift Optimism Despite Watchman Concerns?"
              },
              {
                "id": 140825437,
                "url": "https://finnhub.io/api/news?id=a99a5f13408deb1942a96a7c525ce5d3acb1f184666d2a4f3113429877b3bb89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.",
                "category": "company",
                "datetime": 1783376102,
                "headline": "Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140823712,
                "url": "https://finnhub.io/api/news?id=887f196ea07f6eff8c03f6da7dcafa96bc95e27c2a0cd355be0ac9741ead88cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 24, Jefferies analyst Matthew Taylor cut his price target on Boston Scientific Corporation (NYSE:BSX) to $67 from $100, while keeping a Buy rating on the stock. The analyst stated that a […]",
                "category": "company",
                "datetime": 1783366863,
                "headline": "Is Boston Scientific (BSX) Still One of the Best Stocks to Invest In After Jefferies Slashed Its Target?"
              },
              {
                "id": 140822764,
                "url": "https://finnhub.io/api/news?id=fe90600eeb6ff97658c5de04dce7aa88764c2a60917a72cef873362b63fcdd0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock has fallen 56.5% over the past year, yet the valuation checks still lean toward the shares looking cheap relative to fundamentals and recent news has put a fresh spotlight on whether that gap is justified. The 56.5% one year share price decline raises the question of whether Boston Scientific is being priced for a much weaker outlook than its long term potential would suggest. On one side, the US$1.5b investment in MiRus and option to acquire its TAVR business may...",
                "category": "company",
                "datetime": 1783357655,
                "headline": "Boston Scientific (BSX) Stock Could Be A Bargain After A 57% Slump"
              },
              {
                "id": 140822462,
                "url": "https://finnhub.io/api/news?id=fb503b298eddbe55fa669632c0bf8202960ac03b9180070af394c3342a8ad8b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.",
                "category": "company",
                "datetime": 1783349880,
                "headline": "J&J's MedTech Segment Eyes Another Strong Quarter in Q2"
              },
              {
                "id": 140822234,
                "url": "https://finnhub.io/api/news?id=34698112b1199e0f7bc9572d643559c6fd26098ff2e79778057680b1f52cefe4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2213899495/image_2213899495.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Fiserv and lululemon crashes followed Quant Sell ratings. Click here to see 5 popular stocks that currently warrant investor caution.",
                "category": "company",
                "datetime": 1783344626,
                "headline": "Fiserv And Lululemon Lessons Revisited: 5 Popular Stocks With Quant Sell Ratings"
              },
              {
                "id": 140821327,
                "url": "https://finnhub.io/api/news?id=70b1b8a9d036b4b523706f9e4fef269a5879a76df7fb52cb154b288d0ec06ec9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249178311/image_2249178311.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific stock is ~60% off the highs. Read the latest analysis on the BSX stock here.",
                "category": "company",
                "datetime": 1783339189,
                "headline": "Boston Scientific: The Time Has Come To Catch This Falling Knife"
              },
              {
                "id": 140824210,
                "url": "https://finnhub.io/api/news?id=9b2359ee07b0d1d5814a6df718d2428fee67905fef823c17edb64519be1a2293",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $78 to $65.",
                "category": "company",
                "datetime": 1783338638,
                "headline": "Evercore ISI Group Maintains Outperform on Boston Scientific, Lowers Price Target to $65"
              },
              {
                "id": 140821122,
                "url": "https://finnhub.io/api/news?id=bc1a01e4a3153aeaa577fecd21bc76829a5c301b0d3227ab5365e40dcf8bb30d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.",
                "category": "company",
                "datetime": 1783332000,
                "headline": "Top 10 medtech deals in the first half of 2026"
              },
              {
                "id": 140818095,
                "url": "https://finnhub.io/api/news?id=0ae81bd976d13f0f6f7fd1795088f0ceddbf577be77a77e62fa8a17e9fde9dee",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) offers a compelling value opportunity with a low P/E of 14.56, strong profitability, and solid growth, identified through ChartMill's \"Decent Value\" screen as a quality stock trading at a discount.",
                "category": "company",
                "datetime": 1783327238,
                "headline": "Boston Scientific Corp (NYSE:BSX) Offers Strong Value with High Profitability and Solid Growth"
              },
              {
                "id": 140794039,
                "url": "https://finnhub.io/api/news?id=8831e57c447685f7d89edb07b4c239f2b6fa697dd0711d22279e85d63efc7d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "While a guidance cut has reset expectations, several core Boston Scientific franchises are accelerating. The Neuromodulation and Interventional Oncology businesses both posted organic sales growth of 15% last quarter. This internal momentum in high-value categories contrasts sharply with the new, more cautious company-wide outlook.",
                "category": "company",
                "datetime": 1783013922,
                "headline": "What Could Push BSX Stock Higher From Here?"
              },
              {
                "id": 140792023,
                "url": "https://finnhub.io/api/news?id=1b2cfcadbb8d51bc8a515709b049fcc4c163eaecd6b9d58fce0cdcc7a1a170b7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1783010101,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 140790613,
                "url": "https://finnhub.io/api/news?id=5e76b800b0fc374cefadd6d3e7ba1a0769f4512e4d3b2a238f8ceccbd4a333ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.",
                "category": "company",
                "datetime": 1782976293,
                "headline": "Boston Scientific’s Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 140783907,
                "url": "https://finnhub.io/api/news?id=2b5968346539832e8236a29e95ae655157a3b59de3604d9dbdcd47eee89c429d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the most promising future stocks to buy right now. Stifel cut the price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75 on June 25 and reaffirmed a Buy rating on the shares. The rating update came after the firm hosted five deep left atrial appendage closure […]",
                "category": "company",
                "datetime": 1782935720,
                "headline": "Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why"
              },
              {
                "id": 140771647,
                "url": "https://finnhub.io/api/news?id=172352c6cd8b7125e368559d02937ed3d90704214dec4929e0bcdaef0842ac58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the oversold tech stocks to buy now. On May 18, Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC, a company specializing in advanced biomaterials and medical implants. The deal includes an exclusive option for Boston Scientific to acquire MiRus’s proprietary TAVR system, which […]",
                "category": "company",
                "datetime": 1782818082,
                "headline": "Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option"
              },
              {
                "id": 140764120,
                "url": "https://finnhub.io/api/news?id=15115c8ddf386bc50ddc3fb9d01795b6c1cbd80a889b327a585df6d4ea69da48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.",
                "category": "company",
                "datetime": 1782731798,
                "headline": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic"
              },
              {
                "id": 140760937,
                "url": "https://finnhub.io/api/news?id=e658b11f23fdc2feace59396f6e407ffebd4d74f7340727666a69d38d36e8cb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
                "category": "company",
                "datetime": 1782728295,
                "headline": "3 Value Stocks to Research Further"
              },
              {
                "id": 140760372,
                "url": "https://finnhub.io/api/news?id=1fdeed6a372c14b9674623d2fb294f79e13acd2ba28d078a71c16b17f1784808",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) passes the Caviar Cruise quality screen with 27% ROIC, 34.7% EBIT growth, and strong cash flow. A durable long-term investment candidate.",
                "category": "company",
                "datetime": 1782727231,
                "headline": "Boston Scientific Corp (NYSE:BSX) Meets All Caviar Cruise Quality Criteria for Long-Term Investors"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 95,
            "discarded_article_count": 65
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.3,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；靠近20日高位；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 19528056.666666668,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 18234800,
              "avg_vol_20": 18928075,
              "avg_vol_30": 19528056.666666668,
              "range_pct_10": 0.1077324042629798,
              "range_pct_20": 0.1077324042629798,
              "range_pct_30": 0.12011294265610452,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9337744308744154,
              "dist_to_20d_high": 0.023748918575063616,
              "down_shrink_days": 3,
              "breakout_level_20d": 47.16,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.8969258589511752
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.6
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.6086011379539285,
              "turnoverUsdM": 2175.8370035797075,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BSX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 42.7172,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 2.5,
              "volume_score": 3
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 7.2,
            "take_profit_price": 50.1963,
            "target_multiplier": 1.9,
            "technical_strength": 1.98,
            "take_profit_percent": 9
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2470206121343446,
          "stopLossPercent": 7.217202275907857,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 1.6614,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.61
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 69.57
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.006
    },
    "kdj": {
      "d": 57.4,
      "j": 88.4,
      "k": 67.73,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 47.45
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -225351008,
      "recentSlope": -2795250.8,
      "previousSlope": 909530
    },
    "rsi": 55.76,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 42.4775,
      "position": "SAR喺價下",
      "distancePct": 7.74,
      "previousTrend": "上升"
    },
    "ma50": 47.0118,
    "macd": {
      "macd": -0.3943475569317485,
      "trend": "看漲",
      "signal": -0.889735211423667,
      "histogram": 0.49538765449191846
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 44.4071,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "量價配合",
      "ratio": 2.47,
      "score": 8,
      "avgVolume": 19141725,
      "currentVolume": 47259708
    },
    "derived": {
      "ma20": 44.3505,
      "ma50": 47.0118,
      "prevClose": 46.06,
      "avgVolume10": 21507621,
      "avgVolume20": 19141725,
      "changePercent": -0.04,
      "avgVolumeForScore": 19141725
    },
    "ma_cross": {
      "ma20": 44.3505,
      "ma50": 47.0118,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 44.1825,
      "prevMa50": 47.1446,
      "spreadPct": 5.66,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 42.3353,
      "upper": 46.3657,
      "position": "上半部"
    },
    "rsi_short": 92.79,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 2.47
    }
  }
}

{
  "close": 46.04,
  "volume": 47259708,
  "changePercent": -0.04
}